FDA approves Perrigo, Cobrek dermatitis drug
ALLEGAN, Mich. — The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.
The drug maker said Tuesday that the FDA approved ketoconazole foam in the 2% strength. The drug is a generic version of Stiefel Labs’ Extina, a topical drug used to treat seborrheic dermatitis in patients ages 12 years and older with healthy immune systems.
Extina has annual sales of about $10 million, according to Perrigo.
Rx Response puts tool into play in communities impacted by Irene
WASHINGTON — Rx Response late Monday announced it has activated its Pharmacy Reporting Status Tool to aid storm managers and people in communities affected by Hurricane Irene.
“The Pharmacy Status Reporting Tool can play an important role in storm recovery,” Rx Response program director Erin Mullen said. “First, it lets the public know where they can find an open pharmacy in areas hard hit by the storm, so that they can get the medicines they need. Additionally, it helps emergency managers to better meet medical needs in storm-affected areas.”
The Pharmacy Status Reporting Tool provides real-time information on the operating status of pharmacies in communities affected by Hurricane Irene and will cover pharmacies located in Connecticut, Delaware, Maryland, Massachusetts, New Jersey, North Carolina, New Hampshire, Rhode Island, Vermont, Virginia and Washington, D.C., as well as select counties in New York and Pennsylvania, based on Federal Disaster Declarations.
RxResponse is a partnership comprised of participants in the pharmaceutical supply chain that was created in the wake of Hurricane Katrina to help emergency managers’ by providing information on the status of the pharmaceutical supply chain so that they can more effectively respond to natural disasters, man-made emergencies or a terrorist attack.
Craig Eagle joins corporate advisory board at Provectus
KNOXVILLE, Tenn. — The VP strategic alliances and partnerships for Pfizer’s oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.
Provectus Pharmaceuticals said that the company will benefit from Craig Eagle’s "vast experience in drug development" as the drug maker seeks to commercialize its cancer and dermatological therapies.
Provectus is seeking approval for its novel cancer drug, PV-10, in Australia, and is slated to design a global phase-3 trial for PV-10 as a treatment for metastatic melanoma.